Commure, a healthcare-operations company, announced on May 19 that it had raised $70 million at a $7 billion post-money valuation. The round was led by General Catalyst, with participation from Sequoia Capital, Morgan Stanley, and Kirkland & Ellis. Commure's target is the administrative burden of U.S. healthcare — billing, coding, and revenue-cycle management — which consumes roughly $1 trillion a year. The company says its software operates inside more than 500 healthcare organizations across 3,000-plus sites of care.
The notable claim is the level of autonomy. Commure says its AI agents now complete more than 85% of revenue-cycle work without human intervention, handling tens of billions of dollars in annual payments. That is a different proposition from the AI scribes and chat assistants that dominated healthcare AI a year ago. Those tools drafted text for a human to approve; Commure is selling agents that close administrative tasks end to end, with people supervising the exceptions rather than every transaction.
The deal fits a broader shift in where healthcare AI money is going. Hospital systems are under margin pressure, and back-office automation has a clearer return than clinical AI, which faces regulatory and liability hurdles. Large providers have begun putting numbers on it — UnitedHealth has projected roughly $1 billion in AI-driven savings for 2026 — and investors are funding the vendors that promise to capture that spend. Administrative automation, not diagnosis, is where agentic AI is being deployed at scale first.
Takeaway for learners: "AI agent" is becoming a measurable category, not a buzzword, and the metric to watch is the share of work completed without a human in the loop. When a vendor says 85% of revenue-cycle tasks run autonomously, that number is the product. If you work in or near healthcare, the near-term disruption is in the back office — billing, coding, claims — long before AI touches the exam room. That is where the jobs change first, and where the value is being priced today.